Related Experiment Video

Updated: Aug 12, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

Initial experience with nifekalant hydrochloride (MS-551), a novel class III antiarrhythmic agent, in patients with

K Takenaka1, S Yasuda, S Miyazaki

  • 1Division of Cardiology, Department of Medicine, National Cardiovascular Center, Suita, Osaka, Japan.

Japanese Circulation Journal
|January 12, 2001
PubMed

Insights

Nifekalant hydrochloride, a new Class III antiarrhythmic drug, effectively suppressed dangerous ventricular arrhythmias in patients with severe heart damage. This potassium channel blocker shows promise for treating acute myocardial infarction without negatively impacting hemodynamics.

Area of Science:

  • Cardiology
  • Pharmacology
  • Electrophysiology

Background:

  • Acute myocardial infarction can lead to severe ventricular dysfunction and life-threatening arrhythmias.
  • Class III antiarrhythmic agents target potassium channels to prolong cardiac repolarization.
  • Nifekalant hydrochloride is a novel agent in this class with potential antiarrhythmic properties.

Purpose of the Study:

  • To evaluate the efficacy and safety of nifekalant hydrochloride in patients with acute myocardial infarction and ventricular dysfunction.
  • To assess the antiarrhythmic effects of nifekalant hydrochloride on malignant ventricular tachyarrhythmia.
  • To determine the hemodynamic impact of nifekalant hydrochloride treatment.

Main Methods:

  • Treatment of 4 patients with extensive anterior infarction and severe ventricular dysfunction.
  • Administration of nifekalant hydrochloride at a relatively low dose.
  • Monitoring of ventricular tachyarrhythmia suppression and hemodynamic parameters.

Main Results:

  • Effective suppression of malignant ventricular tachyarrhythmia was observed.
  • The treatment was well-tolerated hemodynamically.
  • A low effective dose of nifekalant hydrochloride was identified.

Conclusions:

  • Nifekalant hydrochloride demonstrates significant therapeutic potential for managing acute myocardial infarction.
  • This potent potassium channel blocker can effectively suppress ventricular tachyarrhythmia.
  • The drug offers a promising treatment option for patients with compromised cardiac function post-infarction.

More Related Videos

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...